Urology Times, Digital Edition, August 2012

The application is seeking an expanded indication of talazoparib plus enzalutamide for mCRPC.

Explore the latest insights on testosterone therapy, its benefits, and practical applications from leading urologists in men's health.

Results from the phase 3 AMPLIFY trial are intended to support an application to the FDA for potential approval of 64Cu-SAR-bisPSMA.

Urologists discuss innovative BPH treatments, emphasizing personalized care, and the importance of ejaculatory preservation.

A recent Urology Times Clinical Forum provided an in-depth overview of current and emerging strategies for managing NMIBC.

The study found differences in genomic alteration frequencies between non-Hispanic Black and non-Hispanic White veterans with metastatic prostate cancer, but showed similar survival outcomes.